Cargando…

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

Prostate cancer harboring BRCA1/2 mutations are often exceptionally sensitive to PARP inhibitors. However, genomic alterations in other DNA damage response genes have not been consistently predictive of clinical response to PARP inhibition. Here, we perform genome-wide CRISPR-Cas9 knockout screens i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsujino, Takuya, Takai, Tomoaki, Hinohara, Kunihiko, Gui, Fu, Tsutsumi, Takeshi, Bai, Xiao, Miao, Chenkui, Feng, Chao, Gui, Bin, Sztupinszki, Zsofia, Simoneau, Antoine, Xie, Ning, Fazli, Ladan, Dong, Xuesen, Azuma, Haruhito, Choudhury, Atish D., Mouw, Kent W., Szallasi, Zoltan, Zou, Lee, Kibel, Adam S., Jia, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845315/ https://www.ncbi.nlm.nih.gov/pubmed/36650183 http://dx.doi.org/10.1038/s41467-023-35880-y

Ejemplares similares

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer
por: Miao, Chenkui, et al.
Publicado: (2022)

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
por: Dillon, Kasia M., et al.
Publicado: (2022)

CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer
por: Tsujino, Takuya, et al.
Publicado: (2021)

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
por: Schina, Aimilia, et al.
Publicado: (2023)

A major genetic accelerator of cancer diagnosis: rs867228 in FPR1
por: Sztupinszki, Zsofia, et al.
Publicado: (2021)

Anti-cancer Effects of a Chemically Modified miR-143 on Bladder Cancer by Either Systemic or Intravesical Treatment
por: Yoshikawa, Yuki, et al.
Publicado: (2019)

The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma
por: Inamoto, Teruo, et al.
Publicado: (2017)

Synthetic miR-143 Exhibited an Anti-Cancer Effect via the Downregulation of K-RAS Networks of Renal Cell Cancer Cells In Vitro and In Vivo
por: Takai, Tomoaki, et al.
Publicado: (2019)

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report
por: Tsujino, Takuya, et al.
Publicado: (2017)

A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients
por: Le Naour, Julie, et al.
Publicado: (2022)

Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models
por: Sztupinszki, Zsófia, et al.
Publicado: (2016)

Characterization of unique PMEPA1 gene splice variants (isoforms d and e) from RNA Seq profiling provides novel insights into prognostic evaluation of prostate cancer
por: Sharad, Shashwat, et al.
Publicado: (2020)

The combination of preoperative platelet count and neutrophil lymphocyte ratio as a prognostic indicator in localized renal cell carcinoma
por: Tsujino, Takuya, et al.
Publicado: (2017)

A Novel Combination RNAi toward Warburg Effect by Replacement with miR-145 and Silencing of PTBP1 Induces Apoptotic Cell Death in Bladder Cancer Cells
por: Takai, Tomoaki, et al.
Publicado: (2017)

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma
por: Prosz, Aurel, et al.
Publicado: (2023)

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma
por: Prosz, Aurel, et al.
Publicado: (2023)

Loss of Nuclear Functions of HOXA10 Is Associated With Testicular Cancer Proliferation
por: Chen, Ruiqi, et al.
Publicado: (2018)

Distinct effect of body mass index by sex as a prognostic factor in localized renal cell carcinoma treated with nephrectomy ~ data from a multi-institutional study in Japan ~
por: Tsutsumi, Takeshi, et al.
Publicado: (2021)

Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer
por: Sztupinszki, Zsofia, et al.
Publicado: (2018)

MicroRNA‐143/Musashi‐2/KRAS cascade contributes positively to carcinogenesis in human bladder cancer
por: Tsujino, Takuya, et al.
Publicado: (2019)

The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells
por: Simoneau, Antoine, et al.
Publicado: (2021)

Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort
por: Komura, Kazumasa, et al.
Publicado: (2019)

ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer
por: Zhou, Yuzhen, et al.
Publicado: (2023)

Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy
por: Lindgaard, Sidsel C., et al.
Publicado: (2022)

DNA Repair Pathway Alterations in Bladder Cancer
por: Mouw, Kent W.
Publicado: (2017)

c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer
por: Maina, Peterson Kariuki, et al.
Publicado: (2016)

Replicative stress in gastroesophageal adenocarcinoma is associated with chromosomal instability and sensitivity to DNA damage response inhibitors
por: Sahgal, Pranshu, et al.
Publicado: (2023)

E3 ligase RFWD3 is a novel modulator of stalled fork stability in BRCA2-deficient cells
por: Duan, Haohui, et al.
Publicado: (2020)

MiR-145 negatively regulates Warburg effect by silencing KLF4 and PTBP1 in bladder cancer cells
por: Minami, Koichiro, et al.
Publicado: (2017)

The CIN4 Chromosomal Instability qPCR Classifier Defines Tumor Aneuploidy and Stratifies Outcome in Grade 2 Breast Cancer
por: Szász, Attila Marcell, et al.
Publicado: (2013)

A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures
por: Diossy, Miklos, et al.
Publicado: (2021)

Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments
por: Munkácsy, Gyöngyi, et al.
Publicado: (2016)

The cancer epigenome: Non‐cell autonomous player in tumor immunity
por: Kato, Shinichiro, et al.
Publicado: (2022)

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
por: Schilder, Jeanne M., et al.
Publicado: (2023)

Analysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer
por: Sharad, Shashwat, et al.
Publicado: (2019)

Prostate Stromal Cells Express the Progesterone Receptor to Control Cancer Cell Mobility
por: Yu, Yue, et al.
Publicado: (2014)

Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene
por: Luo, Jindan, et al.
Publicado: (2019)

Spontaneous Development of Dental Dysplasia in Aged Parp-1 Knockout Mice
por: Fujihara, Hisako, et al.
Publicado: (2019)

From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
por: Mouw, Kent W., et al.
Publicado: (2018)

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_501vlm902l3bae6ohpjjjptgul